Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Shire’s Sales, R&D Heads Shed Light On The Post-Baxalta Road Ahead

Executive Summary

Shire’s Perry Sternberg and Phil Vickers are optimistic about recent launches and products in late stages of development in key rare disease and specialty therapeutic areas, many of which come from Baxalta and other high-profile acquisitions.


Related Content

J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
Deal Watch: Taking Care Of Business Before J.P. Morgan
Shire Exits Biosimilars, Streamlines Oncology Business
Shire Plays Up Xiidra Launch, Downplays Missed Sales Expectations
PIPELINE WATCH: Six Approvals, Five Filings And One Orphan Designation
Goal Finally In Sight For Shire's 'Adderall Beads' Extension Strategy
Shire Seeking 'Tuck-in' Rather Than Large-Scale M&A As It Integrates Dyax And Baxalta
Finally! Shire And Baxalta Sign $32bn Deal To Form Largest Rare Disease Company
Ornskov OK With Cinryze 'Cannibalization' As Shire Buys Dyax (And Keeps Baxalta Guessing)
Shire paying $5.2bn for rare disease specialist NPS


Related Companies